Editors' Pick Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay J-L, Dukovic D, et al. Lancet Neurol. 2014 Jan 22. Epub 1969 Dec 31. PMID: 24461574. Abstract CommentRecommendBookmarkWatch